

Christopher R Gibson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3218771/publications.pdf>

Version: 2024-02-01

33
papers

1,138
citations

471509

17
h-index

395702

33
g-index

35
all docs

35
docs citations

35
times ranked

1383
citing authors

#	ARTICLE	IF	CITATIONS
1	Variability in Human In Vitro Enzyme Kinetics. <i>Methods in Molecular Biology</i> , 2021, 2342, 443-479.	0.9	2
2	Measurement of total liver blood flow in intact anesthetized rats using ultrasound imaging. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00731.	2.4	7
3	Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. <i>Frontiers in Pharmacology</i> , 2021, 12, 786078.	3.5	2
4	Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate. <i>Pharmaceutical Research</i> , 2020, 37, 181.	3.5	4
5	Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1018-1030.	4.7	16
6	Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 110-117.	2.0	2
7	Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective. <i>Drug Discovery Today</i> , 2017, 22, 1447-1459.	6.4	18
8	Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2952-2956.	2.2	8
9	Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape. <i>AAPS Journal</i> , 2015, 17, 462-473.	4.4	43
10	Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery. <i>Future Medicinal Chemistry</i> , 2015, 7, 2351-2369.	2.3	22
11	siRNA-Mediated Knockdown of P450 Oxidoreductase in Rats: A Tool to Reduce Metabolism by CYPs and Increase Exposure of High Clearance Compounds. <i>Pharmaceutical Research</i> , 2014, 31, 3445-3460.	3.5	3
12	Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs – midazolam and odanacatib. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1280-1289.	2.0	17
13	Variability in Human In Vitro Enzyme Kinetics. <i>Methods in Molecular Biology</i> , 2014, 1113, 337-362.	0.9	1
14	Drug-Drug Interaction Studies: Regulatory Guidance and An Industry Perspective. <i>AAPS Journal</i> , 2013, 15, 629-645.	4.4	193
15	Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. <i>Xenobiotica</i> , 2013, 43, 1027-1036.	1.1	19
16	Characterization of Non-Nitrocatechol Pan and Isoform Specific Catechol-O-methyltransferase Inhibitors and Substrates. <i>ACS Chemical Neuroscience</i> , 2012, 3, 129-140.	3.5	35
17	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4127-4157.	3.3	152
18	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4111-4126.	3.3	51

#	ARTICLE	IF	CITATIONS
19	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assesment of prediction methods of human clearance. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4090-4110.	3.3	165
20	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4074-4089.	3.3	105
21	PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4050-4073.	3.3	55
22	Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. <i>Xenobiotica</i> , 2009, 39, 637-648.	1.1	21
23	Discovery of GlyT1 inhibitors with improved pharmacokinetic properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1492-1495.	2.2	23
24	EFFECT OF CYTOCHROMES P450 CHEMICAL INHIBITORS AND MONOCLONAL ANTIBODIES ON HUMAN LIVER MICROSOMAL ESTERASE ACTIVITY. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1361-1366.	3.3	21
25	In vitro metabolism of a thrombin inhibitor and quantitation of metabolically generated cyanide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 39, 1014-1020.	2.8	10
26	INDUCTION OF CYP1A IN THE BEAGLE DOG BY AN INHIBITOR OF KINASE INSERT DOMAIN-CONTAINING RECEPTOR: DIFFERENTIAL EFFECTS IN VITRO AND IN VIVO ON MRNA AND FUNCTIONAL ACTIVITY. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1044-1051.	3.3	5
27	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 62, 157-169.	2.9	2
28	Pharmacokinetics of sodium borocaptate: a critical assessment of dosing paradigms for boron neutron capture therapy. <i>Journal of Neuro-Oncology</i> , 2003, 62, 157-169.	2.9	13
29	Identification of diethylene glycol monobutyl ether as a source of contamination in an ion trap mass spectrometer. <i>Journal of the American Society for Mass Spectrometry</i> , 2003, 14, 1247-1249.	2.8	5
30	BIOACTIVATION OF THE 3-AMINO-6-CHLOROPYRAZINONE RING IN A THROMBIN INHIBITOR LEADS TO NOVEL DIHYDRO-IMIDAZOLE AND IMIDAZOLIDINE DERIVATIVES: STRUCTURES AND MECHANISM USING 13C-LABELS, MASS SPECTROMETRY, AND NMR. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1437-1447.	3.3	12
31	Electrospray Ionization Mass Spectrometry Coupled To Reversed-Phase Ion-Pair High-Performance Liquid Chromatography for Quantitation of Sodium Borocaptate and Application To Pharmacokinetic Analysis. <i>Analytical Chemistry</i> , 2002, 74, 2394-2399.	6.5	11
32	Boron Neutron Capture Therapy of Brain Tumors: Biodistribution, Pharmacokinetics, and Radiation Dosimetry of Sodium Borocaptate in Patients with Gliomas. <i>Neurosurgery</i> , 2000, 47, 608-622.	1.1	49
33	Boron Neutron Capture Therapy of Brain Tumors: Biodistribution, Pharmacokinetics, and Radiation Dosimetry of Sodium Borocaptate in Patients with Gliomas. <i>Neurosurgery</i> , 2000, 47, 608-622.	1.1	39